Myeloma bone disease
NS Callander, GD Roodman - Seminars in hematology, 2001 - Elsevier
Bone destruction is a hallmark of myeloma, with 70% to 80% of patients manifesting bone
involvement. Destruction is mediated through normal osteoclasts (OCLs), which respond to
local osteoclast-activating factors (OAFs) produced by myeloma cells or by other cells in the
local microenvironment. OAFs implicated in myeloma bone disease include tumor necrosis
factor-beta (TNFβ), RANK ligand (RANKL), interleukin-1 (IL-1), parathyroid hormone-related
protein (PTHrP), hepatocyte growth factor (HGH), interleukin-6 (IL-6), tumor necrosis factor …
involvement. Destruction is mediated through normal osteoclasts (OCLs), which respond to
local osteoclast-activating factors (OAFs) produced by myeloma cells or by other cells in the
local microenvironment. OAFs implicated in myeloma bone disease include tumor necrosis
factor-beta (TNFβ), RANK ligand (RANKL), interleukin-1 (IL-1), parathyroid hormone-related
protein (PTHrP), hepatocyte growth factor (HGH), interleukin-6 (IL-6), tumor necrosis factor …